Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Speak Out Rheum: To Prescribe Is Humane (Unless You’re In Texas)

Raymond Scalettar, MD, DSc  |  Issue: November 2022  |  November 7, 2022

You are a rheumatologist in Texas. You are very well trained. Your mentors included some of the leaders in rheumatology, and you are respected by your colleagues and your patients. You know the devastation of untreated rheumatoid arthritis and lupus.

A young woman with recent onset of systemic lupus erythematosus is your new patient. You discuss the indications and side effects with her, and you both agree that, in her case, methotrexate is the drug of choice. You are well aware of the ACR’s guidelines relating to the use of this drug when there are issues of reproductive health.1 The risks of pregnancy with methotrexate are discussed as part of the informed consent process. The patient concurs and takes oral contraceptives for several months before initiating treatment with methotrexate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After starting treatment, and despite using oral contraceptives, your patient becomes pregnant. (Author’s note: Oral contraceptives have a pregnancy prevention failure rate upward of 5%.2) The patient did not realize she was pregnant because her periods have been irregular since she became ill. However, she begins to have pain and severe bleeding, evidence of a spontaneous miscarriage.

A formerly friendly neighbor who is short of cash and is now a bounty hunter becomes aware of her plight and reports her to the authorities.3 The accusation is that she has induced an abortion.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The new pharmacist who refused to renew your methotrexate order for the patient justified that action based on suspicion that you are using it as a abortifacient because you did not indicate on the renewal prescription that it is being used to treat the patient’s lupus.4-6 You note the drug is used for multiple ailments, and it is not the role of a pharmacist to determine the suitability of a medication for a patient.7,8

Your happy days as a rheumatologist are over. The joyful days of being a dedicated physician who believed in the sanctity of the doctor–patient relationship is now a myth. The patient’s constitutionally protected rights and the right to privacy that existed prior to the U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization are over in the state of Texas.

The Aftermath

You are accused of inducing an abortion and await your deposition. You ponder the questions: Did you induce the abortion deliberately? Of course not. Then why did you prescribe methotrexate knowing it can induce abortion? Did you conspire with the patient to end the pregnancy because you both feared the toxic effects on the fetus?

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:EthicsLegal UpdatesOpinionProfessional TopicsSpeak Out Rheum Tagged with:abortionMethotrexatepregnancySpeak Out Rheumatology

Related Articles

    In the Wake of Dobbs v. Jackson Women’s Health Organization

    May 10, 2023

    Since the Supreme Court ruling in June 2022 overturning 50 years of precedent protecting abortion as a constitutional right (Dobbs v. Jackson Women’s Health Organization), states are enacting and implementing new laws to regulate abortion, and medical organizations and healthcare providers are assuming the large task of understanding what the new laws mean for their…

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    Contraception, Abortion & Rheumatic Disease after Dobbs

    December 12, 2022

    PHILADELPHIA—As rheumatologists, we care for patients who may or may not want to become pregnant. We aren’t obstetricians or gynecologists, but several of the drugs we prescribe for active rheumatic disease can negatively affect pregnancy outcomes. It’s imperative we understand how to effectively counsel our patients with rheumatic disease on the risks and benefits of…

    Challenges in Reproductive Health in Rheumatic Disease

    July 11, 2022

    In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences